221 related articles for article (PubMed ID: 8676345)
1. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
[TBL] [Abstract][Full Text] [Related]
2. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
[TBL] [Abstract][Full Text] [Related]
3. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
4. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
5. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
[TBL] [Abstract][Full Text] [Related]
6. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
[TBL] [Abstract][Full Text] [Related]
7. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
[TBL] [Abstract][Full Text] [Related]
8. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
Khan TH; Eno-Amooquaye EA; Searle F; Browne PJ; Osborn HM; Burke PJ
J Med Chem; 1999 Mar; 42(6):951-6. PubMed ID: 10090777
[TBL] [Abstract][Full Text] [Related]
9. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
[TBL] [Abstract][Full Text] [Related]
11. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
[TBL] [Abstract][Full Text] [Related]
12. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
Blakey DC; Burke PJ; Davies DH; Dowell RI; East SJ; Eckersley KP; Fitton JE; McDaid J; Melton RG; Niculescu-Duvaz IA; Pinder PE; Sharma SK; Wright AF; Springer CJ
Cancer Res; 1996 Jul; 56(14):3287-92. PubMed ID: 8764123
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
14. Self-immolative anthracycline prodrugs for suicide gene therapy.
Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
17. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
Spooner RA; Martin J; Friedlos F; Marais R; Springer CJ
Cancer Gene Ther; 2000 Oct; 7(10):1348-56. PubMed ID: 11059693
[TBL] [Abstract][Full Text] [Related]
18. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
19. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
